Unknown

Dataset Information

0

Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity.


ABSTRACT: Current strategies for HIV-1 eradication require the reactivation of latent HIV-1 in resting CD4+ T cells (rCD4s). Global T cell activation is a well-characterized means of inducing HIV-1 transcription, but is considered too toxic for clinical applications. Here, we have explored a strategy that involves a combination of immune activation and the immunosuppressive mTOR inhibitor rapamycin. In purified rCD4s from HIV-1-infected individuals on antiretroviral therapy, rapamycin treatment downregulated markers of toxicity, including proinflammatory cytokine release and cellular proliferation that were induced after potent T cell activation using ?CD3/?CD28 antibodies. Using an ex vivo assay for HIV-1 mRNA, we demonstrated that despite this immunomodulatory effect, rapamycin did not affect HIV-1 gene expression induced by T cell activation in these rCD4s. In contrast, treating activated rCD4s with the immunosuppressant cyclosporin, a calcineurin inhibitor, robustly inhibited HIV-1 reactivation. Importantly, rapamycin treatment did not impair cytotoxic T lymphocyte (CTL) recognition and killing of infected cells. These findings raise the possibility of using rapamycin in conjunction with T cell-activating agents in HIV-1 cure strategies.

SUBMITTER: Martin AR 

PROVIDER: S-EPMC5272184 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity.

Martin Alyssa R AR   Pollack Ross A RA   Capoferri Adam A   Ambinder Richard F RF   Durand Christine M CM   Siliciano Robert F RF  

The Journal of clinical investigation 20170117 2


Current strategies for HIV-1 eradication require the reactivation of latent HIV-1 in resting CD4+ T cells (rCD4s). Global T cell activation is a well-characterized means of inducing HIV-1 transcription, but is considered too toxic for clinical applications. Here, we have explored a strategy that involves a combination of immune activation and the immunosuppressive mTOR inhibitor rapamycin. In purified rCD4s from HIV-1-infected individuals on antiretroviral therapy, rapamycin treatment downregula  ...[more]

Similar Datasets

| S-EPMC7959657 | biostudies-literature
| S-EPMC6950696 | biostudies-literature
| S-EPMC3328678 | biostudies-literature
| S-EPMC7762775 | biostudies-literature
| S-EPMC5621903 | biostudies-literature
2016-09-17 | GSE82061 | GEO
| S-EPMC5354304 | biostudies-literature
| S-EPMC5892446 | biostudies-literature
| S-EPMC8139712 | biostudies-literature
2022-02-10 | GSE196091 | GEO